Ultragenyx reaffirms full-year revenue guidance after posting record Q2 2026 sales, targeting regulatory submissions and profitability milestones.
Ultragenyx plans to submit two gene therapy pre-market approval filings in August or September 2026, management said during its Q2 2026 earnings call. The company also set a profitability target for 2027, citing strong execution across development and commercial operations.
The biotech firm reported its highest quarterly revenue to date in Q2 2026, supporting its reaffirmed full-year revenue guidance. Prior quarters showed steady growth, with the company expanding its pipeline and commercial footprint.
No immediate market reaction was disclosed in the call, though the timeline for regulatory filings and profitability may influence investor sentiment.